Liver Specialist Refutes Study Claiming Hepatitis C Drug Dangers
Editor’s note: Responding to a report on dangers associated with taking direct-acting antiviral (DAA) agents for hepatitis C, Douglas Dieterich, MD, director of the Institute for Liver Medicine at the Mount Sinai Health System in New York City, voiced his opinions on the findings. The ISMP report cited 524 cases of liver failure and 1,058 cases of severe liver damage in patients taking one of nine DAAs.
What are some misconceptions that physicians and patients could take from the study?
That the two drugs mentioned Sovaldi and Harvoni are unsafe. It's quite the contrary, they are very safe and they are the safest drugs to use in patients with severely decompensated liver disease—which were the ones who had the complications in this study...
Medscape Medical News, January 26, 2017
Report Cites Liver Failure Risk With New Hepatitis C Drugs
January 26, 2017
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- Treating Elderly HCV Patients
- FibroScan® Understanding The Results
- Staging Cirrhosis
- Is There A Natural Way To Improve Liver Fibrosis?